Antiretrovirals
New US pediatric dosing for lopinavir/r
The lopinavir/r (Kaletra) tablet and oral solution labels were updated to include dosing recommendations for pediatric patients 14 days to 6 months of age and from 12 to 18 years of age.
Dosing in children (14 days – 18 years of age) is based on body weight or body surface area (size) see Table 1. For full details see the FDA announcement and new product information.
Table 1. Pediatric dosing recommendations for patients 6 months to 18 years of age *
|
Body weight (kg) |
Body surface area (m2) |
Recommended number of 100/25 mg tablets, twice daily |
|---|---|---|
|
15 to 25 |
≥0.6 to <0.9 |
2 |
|
>23 to 35 |
≥0.9 to <1.4 |
3 |
|
>35 |
≥1.4 |
4 (or two 200/50 mg tablets) |
* Based on body weight or body surface area for lopinavir/r tablets (without concomitant efavirenz, neviraprine, fosamprenavir, or nelfinavir)
Source: FDA list serve (23 June 2008).
http://www.fda.gov/oashi/aids/listserve/listserve2008.html#62308
Links to external websites are current at time of posting but not maintained.